Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

ALDX vs AVDL: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

AVDL Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 9–0 Matrix Metrics)

AVDL Overall Winner 6-Pillar Tally: ALDX 0 – 5 AVDL (1 Tie) Matrix Metrics: ALDX 0 – 9 AVDL

As of Nov 20, 2026, Avadel Pharmaceuticals plc Ordinary Share (AVDL) is the stronger overall head-to-head candidate over Aldeyra Therapeutics, Inc. (ALDX) in the Tradestie Institutional Equity Comparison Engine, winning 9–0 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ALDX carries a Unified Composite Score of 40.1/100 (SELL) at $0.84 (N/M Forward P/E, 0.0% operating margin), whereas AVDL carries 62.9/100 (BUY) at $21.64 (28.8x Forward P/E, 2.5% operating margin).

  • Technical & Structure Timing Caution: ALDX is currently in a Breakdown options structure phase (RSI 60.6); meanwhile AVDL trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 62.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ALDX vs AVDL
ALDX NASDAQ
Aldeyra Therapeutics, Inc.
Pharmaceutical Preparations
$0.84
+16.39% 1D
Market Cap $43.6M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.43β · 94% Vol
Unified Composite Score
40.1 / 100 SELL
Tech 15.0 Fund 45.0 Flow 69.0 Mom 58.9
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 61
RSI-14: 60.6 · SMA20: $0.65 · SMA50: $0.90
AVDL NASDAQ Head-to-Head Winner
Avadel Pharmaceuticals plc Ordinary Share
Pharmaceutical Preparations
$21.64
+0.05% 1D
Market Cap $2.1B
TTM Revenue $249M
Forward P/E 28.8x
Beta / 30D Vol 0.14β · 2% Vol
Unified Composite Score
62.9 / 100 BUY
Tech 75.0 Fund 60.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (1.4% over 20 days), RSI 62
RSI-14: 62.3 · SMA20: $21.56 · SMA50: $21.50

6-Pillar Scorecard Institutional Category Breakdown (ALDX 0 – 5 AVDL)

Columns: Metric · ALDX · AVDL
1. Valuation Multiples AVDL
Forward P/E N/M 28.8x
Trailing P/E N/M 16.8x
PEG Ratio N/M 0.07x
EV / Revenue N/M 8.5x
2. Growth & Scale AVDL
Revenue Growth (YoY) +0.0% +54.9%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $249M
Market Cap $43.6M $2.1B
3. Profitability & Quality AVDL
Gross Margin N/A 94.9%
Operating Margin 0.0% 2.5%
Net Profit Margin 0.0% -0.1%
Return on Equity (ROE) -45.3% -0.3%
4. Balance Sheet & Cash Flow AVDL
Cash Generation (TTM) -$19M $2.7M EBITDA
Cash Flow Margin N/A 1.1% EBITDA Mgn
Net Cash / Leverage $41M Net Cash $1.01 Book/Sh · -0.3% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning AVDL
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 247.8% (29th %ile) 2.4% (<1st %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markup
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Drug Manufacturers - Specialty & Generic Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ALDX (0) vs AVDL (9)
Institutional Metric ALDX AVDL Criterion Row Edge
Market Capitalization
Scale
$43.6M $2.1B Larger Scale AVDL
Trailing P/E Ratio
Valuation
N/M 16.8x Lower Multiple AVDL
Forward P/E Ratio
Valuation
N/M 28.8x Lower Multiple AVDL
Revenue Growth (YoY)
Growth
+0.0% +54.9% Higher Growth AVDL
Operating Margin (TTM)
Profitability
0.0% 2.5% Higher Margin AVDL
Net Profit Margin
Profitability
0.0% -0.1% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-45.3% -0.3% Higher ROE AVDL
52-Week Range Position
Momentum
6% ($1–$6) 89% ($6–$24) Stronger Trend AVDL
Beta / 30D Volatility
Risk Regime
0.43β · 94% Vol 0.14β · 2% Vol Lower Realized Risk AVDL
Unified Institutional Score
Composite Signal
40.1 / 100 (SELL) 62.9 / 100 (BUY) Higher Composite AVDL
Trailing 12M Revenue (USD)
Operating Scale
N/A $249M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 94.9% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev 0.07x PEG · 8.5x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$19M ($41M Net Cash) $2.7M EBITDA ($1.01 Book/Sh · -0.3% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ALDX +28.16 pp
ALDX: +28.81% · AVDL: +0.65%
3M Horizon ALDX +15.79 pp
ALDX: +9.47% · AVDL: -6.32%
6M Horizon ALDX +15.79 pp
ALDX: +9.47% · AVDL: -6.32%
1Y Horizon ALDX +15.79 pp
ALDX: +9.47% · AVDL: -6.32%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ALDX vs AVDL. Trailing 12-month operating profitability (ALDX 0.0% vs AVDL 2.5%) and valuation multiples (ALDX N/M vs AVDL 28.8x Forward P/E) are benchmarked directly in Pillar 4 below.

ALDX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-45.3% · N/M
AVDL ADR TTM Benchmark FX-Normalized USD
TTM Revenue$249M
Gross Margin94.9%
Op. Margin2.5%
ROE / Fwd P/E-0.3% · 28.8x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ALDX BREAKDOWN
169d in phase · OBV NEUTRAL
Current IV 247.8%
IV Percentile 29th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ALDX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
AVDL UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 2.4%
IV Percentile <1st %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact AVDL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ALDX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $43.6M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
AVDL Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $2.1B market capitalization and 2.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ALDX vs AVDL Key Questions & Quantitative Answers

As of Nov 20, 2026, Avadel Pharmaceuticals plc Ordinary Share (AVDL) is the stronger overall head-to-head candidate over Aldeyra Therapeutics, Inc. (ALDX) in the Tradestie Institutional Equity Comparison Engine, winning 9–0 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ALDX carries a Unified Composite Score of 40.1/100 (SELL) at $0.84 (N/M Forward P/E, 0.0% operating margin), whereas AVDL carries 62.9/100 (BUY) at $21.64 (28.8x Forward P/E, 2.5% operating margin). Technical & Structure Timing Caution: ALDX is currently in a Breakdown options structure phase (RSI 60.6); meanwhile AVDL trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 62.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

AVDL leads the Growth & Scale pillar: ALDX posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with AVDL at +54.9% YoY revenue growth and +0.0% YoY earnings growth on $249M TTM revenue (94.9% gross margin, 2.5% operating margin). On trailing 12-month operating scale, ALDX generates N/A in USD-normalized revenue versus $249M for AVDL. In operating R&D and SG&A reinvestment, ALDX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for AVDL.

AVDL screens cheaper on headline valuation multiples. ALDX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas AVDL trades at 28.8x Forward P/E, 16.8x Trailing P/E, 0.07x PEG, and 8.5x EV/Revenue (1.1% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ALDX (-45.3% ROE) versus AVDL (-0.3% ROE) capital efficiency.

In options market volatility and institutional positioning, ALDX carries 247.8% implied volatility (29th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (0.43β · 94% Vol realized risk). By comparison, AVDL carries 2.4% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.14β · 2% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.